Fine needle samplings of tumors were used to measure SPF by flow cytometry before treatment ( Day 0 ) , and to assess the MDR phenotype using semiquantified reverse transcriptase polymerase chain reaction and immunocytochemistry , before and after ( Days 8 and 28 ) the first cycle of chemotherapy .
